Mersana Raises $4M in Note Placement

Mersana Therapeutics has completed a convertible note placement worth $4 million, officials of the Cambridge, MA-based cancer drug developer told Mass High Tech. The new funding brings Mersana’s total private investment raised to date to about $36 million, according to Mass High Tech; Fidelity Biosciences, Harris & Harris Group, PureTech Ventures, ProQuest Investments, and Rho Ventures are all backers of the firm. Mersana’s lead drug candidate began early stage clinical trials in 2007.

Rebecca is Xconomy's co-founder. Follow @

Trending on Xconomy